Title |
Therapeutic Advancements in Multiple Myeloma
|
---|---|
Published in |
Frontiers in oncology, September 2014
|
DOI | 10.3389/fonc.2014.00241 |
Pubmed ID | |
Authors |
Alessandro Gozzetti, Veronica Candi, Giulia Papini, Monica Bocchia |
Abstract |
Multiple myeloma survival has significantly improved in the latest years due to a broad spectrum of novel agents available for treatment. The introduction of thalidomide, bortezomib, and lenalidomide together with autologous stem-cell transplantation has considerably increased complete remission rate and progression-free survival resulting ultimately in prolonged survival in myeloma patients. Moreover, novel strategies of treatment such as consolidation and maintenance are being used to further implement responses. Finally, a number of new drugs such as carfilzomib and pomalidomide are already in clinical practice, making the future of myeloma patients brighter. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 2% |
Russia | 1 | 2% |
Unknown | 58 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 12 | 20% |
Student > Bachelor | 8 | 13% |
Student > Master | 8 | 13% |
Unspecified | 7 | 12% |
Other | 6 | 10% |
Other | 13 | 22% |
Unknown | 6 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 22 | 37% |
Agricultural and Biological Sciences | 8 | 13% |
Unspecified | 7 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
Biochemistry, Genetics and Molecular Biology | 3 | 5% |
Other | 7 | 12% |
Unknown | 9 | 15% |